UNOFFICIAL COPY 25 RS BR 324
1 AN ACT relating to Ibogaine research in the Commonwealth.
2 Be it enacted by the General Assembly of the Commonwealth of Kentucky:
3 SECTION 1. A NEW SECTION OF KRS CHAPTER 218A IS CREATED TO
4 READ AS FOLLOWS:
5 As used in Sections 1 to 4 of this Act:
6 (1) "Department" means the Department of Agriculture; and
7 (2) "Private entity" means an incorporated business licensed to operate in the
8 Commonwealth.
9 SECTION 2. A NEW SECTION OF KRS CHAPTER 218A IS CREATED TO
10 READ AS FOLLOWS:
11 It is the declared policy of the Commonwealth that ibogaine is worthy of clinical
12 research, trials, and studies as a potential viable therapeutic treatment of opioid
13 dependence and any other co-occurring mental health disorders. The purposes of
14 Sections 1 to 4 of this Act are to:
15 (1) Promote the research and study of ibogaine as a treatment of opioid dependence
16 and any other co-occurring mental health disorders; and
17 (2) Promote the creation of an industry in the Commonwealth related to the study of
18 ibogaine.
19 SECTION 3. A NEW SECTION OF KRS CHAPTER 218A IS CREATED TO
20 READ AS FOLLOWS:
21 (1) There is hereby established in the State Treasury a trust and agency fund entitled
22 the ibogaine research fund, to be administered by the department for the purpose
23 of allowing private entities that operate in the Commonwealth to partially cover
24 the costs of ibogaine research in the Commonwealth.
25 (2) The fund may receive state appropriations, gifts, grants, federal funds, and any
26 other funds both public and private. Money deposited in the fund is hereby
27 appropriated for purposes set out in Sections 1 to 4 of this Act.
Page 1 of 3
XXXX 2/18/2025 11:15 AM Jacketed

UNOFFICIAL COPY 25 RS BR 324
1 (3) Notwithstanding KRS 45.229, any unallocated or unencumbered balances in the
2 fund shall be invested as provided in KRS 42.500(9), and any interest or other
3 income earned from the investments, along with the unallotted or unencumbered
4 balances in the fund, shall not lapse but shall be carried forward for into the next
5 fiscal year.
6 SECTION 4. A NEW SECTION OF KRS CHAPTER 218A IS CREATED TO
7 READ AS FOLLOWS:
8 A private entity that applies for a distribution from the fund established in Section 3 of
9 this Act shall:
10 (1) Conduct and fund research in the Commonwealth related to:
11 (a) Ibogaine, including pharmaceutical development and the efficacies of
12 ibogaine for the treatment of opioid dependence and any other co-occurring
13 mental health disorders;
14 (b) The health effects, including the potential risks or side effects, of the use of
15 ibogaine; and
16 (c) The efficacy and potential health effects of various ibogaine delivery
17 methods;
18 (2) Review current and future ibogaine research literature, clinical studies, and
19 clinical trials;
20 (3) Monitor, to the extent that appropriate and sufficient data is available, patient
21 outcomes in states and countries that allow ibogaine research or usage; and
22 (4) Submit an application to the federal Drug Enforcement Administration to:
23 (a) Allow for it to conduct clinical research, trials, and studies of ibogaine as a
24 potential viable therapeutic treatment of opioid dependence and any other
25 co-occurring mental health disorders;
26 (b) Provide a detailed description of the planned strategy for securing an
27 approved "Investigation of New Drug" (IND) application from the Federal
Page 2 of 3
XXXX 2/18/2025 11:15 AM Jacketed

UNOFFICIAL COPY 25 RS BR 324
1 Drug Administration (FDA). IND approval from the FDA is a prerequisite
2 for clinical research and trials; and
3 (c) Provide a detailed clinical trial design including a description of the
4 composition of the entity's clinical trial team by expertise, clinical trial
5 participant recruitment plan, detailed patient screening criteria, cardiac
6 safety protocols, administration protocols, aftercare, post-acute treatment
7 support plan, and data integrity plan.
Page 3 of 3
XXXX 2/18/2025 11:15 AM Jacketed

[DELETED:  C  2  J A B S R A ( " ( " e m a i b l t o i t C S R I i t d p o t C t i i w o c r t a s a a p v t t o o d a a o c m h d T p o S ( P a ( P i S R ( T t o a p e t o t ( T f m r s a o f b p a p M d i t f i h a]
[DELETED:  C  2  J ( N f s b i a p i K 4 a i b f S R A t ( C ( I i p d a t e o i m ( T i ( T e a p h e o v i d m ( R c a f i r l c s a c ( M t t e t a a s d i a p o ( S ( A p v t t o o d a c ( P a d d o t p s f s a a]
[DELETED:  C  2  J D f ( P a d c t d i a d o t c o t e c t t b e c t p p d p s c c s p a p a p t s]